JP2018531987A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531987A5 JP2018531987A5 JP2018529516A JP2018529516A JP2018531987A5 JP 2018531987 A5 JP2018531987 A5 JP 2018531987A5 JP 2018529516 A JP2018529516 A JP 2018529516A JP 2018529516 A JP2018529516 A JP 2018529516A JP 2018531987 A5 JP2018531987 A5 JP 2018531987A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- tautomer
- stereoisomer
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000000623 heterocyclic group Chemical group 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 21
- 239000001257 hydrogen Substances 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 125000000547 substituted alkyl group Chemical group 0.000 claims 18
- 150000002431 hydrogen Chemical class 0.000 claims 17
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000004452 carbocyclyl group Chemical group 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000002252 acyl group Chemical group 0.000 claims 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000003107 substituted aryl group Chemical group 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000002837 carbocyclic group Chemical group 0.000 claims 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 108010016626 Dipeptides Proteins 0.000 claims 2
- 101150113681 MALT1 gene Proteins 0.000 claims 2
- 102000057613 Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Human genes 0.000 claims 2
- 108700026676 Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102000046016 B-Cell CLL-Lymphoma 10 Human genes 0.000 claims 1
- 108700024832 B-Cell CLL-Lymphoma 10 Proteins 0.000 claims 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 1
- 101150074953 BCL10 gene Proteins 0.000 claims 1
- 102000007443 Deubiquitinating Enzyme CYLD Human genes 0.000 claims 1
- 108010086291 Deubiquitinating Enzyme CYLD Proteins 0.000 claims 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021135770A JP2021193093A (ja) | 2015-08-28 | 2021-08-23 | Ｍａｌｔ１阻害剤およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562211629P | 2015-08-28 | 2015-08-28 | |
| US62/211,629 | 2015-08-28 | ||
| US201562256672P | 2015-11-17 | 2015-11-17 | |
| US62/256,672 | 2015-11-17 | ||
| PCT/US2016/049038 WO2017040304A1 (en) | 2015-08-28 | 2016-08-26 | Malt1 inhibitors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021135770A Division JP2021193093A (ja) | 2015-08-28 | 2021-08-23 | Ｍａｌｔ１阻害剤およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018531987A JP2018531987A (ja) | 2018-11-01 |
| JP2018531987A5 true JP2018531987A5 (enExample) | 2019-10-03 |
| JP6989505B2 JP6989505B2 (ja) | 2022-01-05 |
Family
ID=58188144
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529516A Active JP6989505B2 (ja) | 2015-08-28 | 2016-08-26 | Ｍａｌｔ１阻害剤およびその使用 |
| JP2021135770A Pending JP2021193093A (ja) | 2015-08-28 | 2021-08-23 | Ｍａｌｔ１阻害剤およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021135770A Pending JP2021193093A (ja) | 2015-08-28 | 2021-08-23 | Ｍａｌｔ１阻害剤およびその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10711036B2 (enExample) |
| EP (1) | EP3341007B1 (enExample) |
| JP (2) | JP6989505B2 (enExample) |
| WO (1) | WO2017040304A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018020474A1 (en) | 2016-07-29 | 2018-02-01 | Lupin Limited | Substituted thiazolo-pyridine compounds as malt1 inhibitors |
| BR112018076800A2 (pt) * | 2016-07-29 | 2019-04-02 | Toray Industries, Inc. | derivado de guanidina, medicamento, inibidor da proteína 1 da translocação de linfoma de tecido linfóide associado com mucosa, e, agente terapêutico ou profilático. |
| BR112019001824A2 (pt) | 2016-07-29 | 2019-05-07 | Lupin Limited | compostos de tiazol-piridina substituídos como inibidores de malt1 |
| EP3731848A4 (en) * | 2017-12-28 | 2021-12-15 | The General Hospital Corporation | TARGETING OF THE CBM-SIGNALOSOME COMPLEX FOR INDUCING REGULATORY T-CELLS TO CITIZE INFLAMMATION OF THE TUMOR MICRO-ENVIRONMENT |
| WO2019159097A1 (en) * | 2018-02-14 | 2019-08-22 | Sun Pharmaceutical Industries Limited | Crystalline polymorphic forms of acalabrutinib |
| ES2992431T3 (es) * | 2018-06-18 | 2024-12-12 | Janssen Pharmaceutica Nv | Derivados de pirazol como inhibidores de MALT1 |
| BR112020025844A2 (pt) * | 2018-06-18 | 2021-03-23 | Janssen Pharmaceutica Nv | derivados de pirazol como inibidores de malt1 |
| WO2020076889A1 (en) * | 2018-10-09 | 2020-04-16 | The Research Institute At Nationwide Children's Hospital | Anticancer rocaglamide derivatives |
| CN111358959B (zh) * | 2019-10-10 | 2021-03-26 | 鹿文葆 | Roquin1蛋白及其编码基因在制备抑制肿瘤的药物中的应用 |
| CN111686111B (zh) * | 2020-06-09 | 2023-06-13 | 南方医科大学 | Malt1蛋白酶抑制剂在制备非小细胞肺癌治疗药物中的应用 |
| US20230391781A1 (en) * | 2020-10-16 | 2023-12-07 | Rheos Medicines, Inc. | Malt1 modulators and uses thereof |
| CN113057957A (zh) * | 2021-03-30 | 2021-07-02 | 福建中医药大学 | 葛杜宁及其衍生物在制备抗氧化药物和/或化妆品及治疗类风湿性关节炎药物中的用途 |
| CN113024565B (zh) * | 2021-03-31 | 2022-09-13 | 上海启甄环境科技有限公司 | 一种放射性同位素碳-14标记依鲁替尼及其合成方法 |
| US20250115636A1 (en) * | 2022-02-03 | 2025-04-10 | Purdue Research Foundation | Peptidomimetic inhibitors of protein n-terminal methyltransferase 1, composition, and method of use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5210272A (en) | 1990-02-16 | 1993-05-11 | Prototek, Inc. | Process for forming a fluoromethyl ketone |
| WO1997048687A1 (en) | 1996-06-18 | 1997-12-24 | Warner-Lambert Company | Process for the preparation of chiral keto-heterocycles of basic amino acids |
| DE60036812T2 (de) | 1999-07-07 | 2008-07-17 | Astrazeneca Uk Ltd. | Chinazolin derivate |
| JP5479105B2 (ja) | 2007-11-05 | 2014-04-23 | 国立大学法人佐賀大学 | 新規ユビキリン結合性小分子 |
| WO2012071414A2 (en) | 2010-11-22 | 2012-05-31 | Board Of Regents Of The University Of Nebraska | Quinoxaline compounds and uses thereof |
| BR112015010504A2 (pt) * | 2012-11-09 | 2017-12-05 | Univ Cornell | uso de inibidores de molécula pequena de malt1, método de identificação de um modulador de molécula pequena de malt1, e composição farmacêutica |
| JP6778114B2 (ja) | 2014-04-14 | 2020-10-28 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | イミド系タンパク質分解モジュレーター及び関連する使用方法 |
| SG11201607895PA (en) | 2014-05-28 | 2016-12-29 | Novartis Ag | Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors |
| WO2018085247A1 (en) | 2016-11-01 | 2018-05-11 | Cornell University | Compounds for malt1 degradation |
-
2016
- 2016-08-26 EP EP16842694.8A patent/EP3341007B1/en active Active
- 2016-08-26 WO PCT/US2016/049038 patent/WO2017040304A1/en not_active Ceased
- 2016-08-26 JP JP2018529516A patent/JP6989505B2/ja active Active
- 2016-08-26 US US15/755,951 patent/US10711036B2/en active Active
-
2021
- 2021-08-23 JP JP2021135770A patent/JP2021193093A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018531987A5 (enExample) | ||
| KR102566924B1 (ko) | 케모카인 수용체 조절제 및 이의 용도 | |
| JP6806562B2 (ja) | ｅＩＦ２α経路の調節因子 | |
| JP5898067B2 (ja) | がん及び非新生物性状態の治療方法 | |
| FI4073065T3 (fi) | Uusia metyylikinatsolinonijohdannaisia | |
| CY1119880T1 (el) | Παραγωγα πυρρολοπυριμιδινης για χρηση στη θεραπεια ιικων λοιμωξεων | |
| JP2002540156A (ja) | 抗ウイルス治療用チアジアゾリルウレアまたはチオウレア誘導体 | |
| AU2018360855A1 (en) | Modulators of the integrated stress pathway | |
| JP2012518029A5 (enExample) | ||
| JP2014503567A5 (enExample) | ||
| JP2019515908A5 (enExample) | ||
| EP4327877A3 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| US20230233557A1 (en) | Formulations comprising heterocyclic protein kinase inhibitors | |
| JP2016540803A5 (enExample) | ||
| KR20230075524A (ko) | N-[5-(아미노술포닐)-4-메틸-1,3-티아졸-2-일]-n-메틸-2-[4-(2-피리디닐)-페닐]-아세트아미드 유리 염기 반수화물, 그의 제조 방법 및 용도 | |
| TW200529811A (en) | HIV protease inhibiting compounds | |
| JP2019519512A5 (enExample) | ||
| JP2005526024A5 (enExample) | ||
| JP2017532316A5 (enExample) | ||
| JP2015522592A5 (enExample) | ||
| US20190202826A1 (en) | Phosphotidylinositol 3-Kinase Inhibitors | |
| JP2018534316A5 (enExample) | ||
| US9676727B2 (en) | Myxovirus therapeutics, compounds, and uses related thereto | |
| JP2017529386A5 (enExample) | ||
| US20230063768A1 (en) | Immunophilin binding agents and uses thereof |